Search | Clinical Trials Finder

Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Interventions: Tabelecleucel, Pembrolizumab; Biological
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Duarte, California • Palo Alto, California • Boston, Massachusetts + 3 more

Conditions: Carcinoma, Hepatocellular
Interventions: Atezolizumab, Bevacizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 5 more

Conditions: Healthy Volunteers
Interventions: PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo; Combination Product · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Asthma
Interventions: AZD7594; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 10
States / cities: Rolling Hills Estates, California • Miami, Florida • Miami Lakes, Florida + 7 more

Conditions: Celiac Disease
Interventions: Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C; Drug · Other
Lead sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: ZEN003694, Enzalutamide; Drug
Lead sponsor: Zenith Epigenetics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Detroit, Michigan + 4 more

Conditions: Parkinson's Disease (PD)
Interventions: MR-005 (MedRhythms, Inc., Portland, ME); Device
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Salt Lake City, Utah

Conditions: Schizophrenia, Parkinson's Disease
Interventions: O-15 Water, 18F-Fluoro-L-dopa; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinsons Disease (PD)
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Safety and Tolerability
Interventions: inhaled human insulin, Insulin Lispro (Humalog U-100); Drug
Lead sponsor: Dance Biopharm Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Parkinson's Disease (PD)
Interventions: Shame Control (Baseline), Standard of Care Deep Brain Stimulation, Illumina 3D Deep Brain Stimulation, Illumina 3D Deep Brain Stimulation Reduced Amplitude, Illumina 3D Deep Brain Stimulation Higher Amplitude; Device
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Melanoma
Interventions: Intervention Arm, Control; Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Loma Linda, California • Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo; Drug · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 907 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 24
States / cities: La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan

Conditions: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions: Bempegaldesleukin, Pembrolizumab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions: M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine; Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma, Breast Cancer
Interventions: Zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 7
States / cities: West Hollywood, California • Greenwood Village, Colorado • Norwalk, Connecticut + 4 more

Conditions: Advanced Solid Tumors
Interventions: CPI-1205, ipilimumab; Drug
Lead sponsor: Constellation Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas

Conditions: NSCLC Stage IV, NSCLC, Stage IIIC
Interventions: Primary Immune Response (PIR) test by Biodesix, Inc.; Diagnostic Test
Lead sponsor: Addario Lung Cancer Medical Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: San Carlos, California • Chicago, Illinois

Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection, Cyclophosphamide, Fludarabine; Biological · Procedure · Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions: Incobotulinum Toxin A, placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 20 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urothelial Carcinoma
Interventions: Carboplatin, Gemcitabine, Atezolizumab, Docetaxel; Drug
Lead sponsor: Nabil Adra; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Indianapolis, Indiana • Omaha, Nebraska • Albuquerque, New Mexico + 1 more

Conditions: Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 19
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more

Search by objective public record fields.

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson Disease

PET Scanning in Parkinson s Disease

Neuroimaging of Parkinson's

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Automated Image-Guided Programming of Deep Brain Stimulation (DBS) for Parkinson's Disease

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia